Clopidogrel is a prodrug that is metabolized by CYP2C19 into its active metabolite. Polymorphisms in the enzyme can lead to reduced function causing decreased levels of the active metabolite of clopidogrel. The POPular Genetics Trial compared outcomes between carriers (received ticagrelor or prasugrel) and non-carriers (received clopidogrel) undergoing primary PCI for STEMI. The genotype-guided approach was non-inferior to standard treatment in thrombotic events and had fewer bleeding events.
Is genotyping routinely considered when choosing between P2Y12 inhibitors? Will genotyping become the standard of practice? What other medications may benefit from using genotype-guided approaches?
-
Like
Easy one-click social registration
Is this safe?We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.
ORWhy we require registering to vote
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.
Log in or create an account to comment
Social Login
Email Login
Log in via Email
Back to Social Login
Create Your Account